Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response - Pace, A.; Vidiri, A.; Galiè, E.; Carosi, M.; Telera, S.; Cianciulli, A. M.; Canalini, P.; Giannarelli, D.; Jandolo, B.; Carapella, C. M. (Annals of oncology, 2003)
Keywords: Administration, Oral; Adult; Aged; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Brain Neoplasms - diagnostic imaging; Brain Neoplasms - drug therapy; Brain Neoplasms - pathology; Chemotherapy; Dacarbazine - administration & dosage; Dacarbazine - analogs & derivatives; Dacarbazine - therapeutic use; Disease Progression; Disease-Free Survival; epilepsy; Female; Glioma - diagnostic imaging; Glioma - drug therapy; Glioma - pathology; Humans; Key words: chemotherapy; low-grade glioma; Male; Medical sciences; Middle Aged; Neoplasm Staging; Pharmacology. Drug treatments; Quality of Life; Radiography; Seizures - etiology; Seizures - prevention & control; Temozolomide; Treatment Outcome; Antineoplastic agent; Histological grading; Human; epilepsy; Nervous system diseases; Treatment efficiency; Oral administration; Malignant tumor; Malignant glioma; Alkylating agent; Chemotherapy; Treatment; low-grade glioma; Low malignancy; Central nervous system disease; Phase II trial; Tumor progression; Temozolomide; Low grade